CLAIMS

1. Use of an antibody drug conjugate (ADC) comprising an anti-CD19 antibody and a pyrrolobenzodiazepine dimer in the manufacture of a medicament for treating a disorder in an individual, wherein the an effective amount of the ADC and polatuzumab vedotin is to be administered to the individual.

2. Use of polatuzumab vedotin in the manufacture of a medicament for treating a disorder in an individual, wherein an effective amount of polatuzumab vedotin and an antibody drug conjugate (ADC) comprising an anti-CD19 antibody and a pyrrolobenzodiazepine dimer are to be administered to the individual.

3. The use according to claim 1 or 2, wherein the individual is human.

4. The use according to any preceding claim, wherein the individual is undergoing treatment with polatuzumab vedotin.

5. The use according to any preceding claim, wherein the individual has undergone treatment with polatuzumab vedotin.

6. The use according to any preceding claim, wherein the individual is refractory to treatment, or further treatment, with polatuzumab vedotin.

7. The use according to any one of the preceding claims, wherein the treatment has increased efficacy as compared to monotherapy with either the ADC or polatuzumab vedotin alone.

8. The use according to any preceding claim, wherein the disorder is a proliferative disease.

9. The use according to claim 8, wherein the disorder is characterised by the presence of a neoplasm comprising CD19+ve cells.

10. The use according to any one of preceding claims, wherein the disorder is cancer.


11. The use according to any one of the preceding claims, wherein the individual has, or has been determined to have, a cancer which expresses CD19 or CD19+ve tumour-associated non-tumour cells, such as CD19+ve infiltrating cells.

12. The use according to any one of the preceding claims, wherein the disorder is selected from the group comprising: non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Burkitt lymphoma, Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Waldenström Macroglobulinemia (WM), and Marginal Zone B-cell lymphoma (MZBL), and leukemias such as Hairy cell leukemia (HCL),

Hairy cell leukemia variant (HCL-v), chronic lymphocytic leukemia (CLL) including Richter syndrome, and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).


13. The use according to any one of the preceding claims wherein the antibody comprises the CDRs of SEQ ID Nos: 2 and 8.

14. The use according to any one of the preceding claims wherein the PBD is of formula (III):



wherein R^{LL} is a linker for connection to the antibody.


15. The use according to any one of the preceding claims wherein the ADC has the following structure:



wherein Ab is the anti-CD19 antibody.

16. A composition comprising (i) an antibody drug conjugate (ADC) comprising an anti-CD19 antibody and a pyrrolobenzodiazepine dimer(PBD); and (ii) polatuzumab vedotin.

17. The composition according to claim 16, wherein the PBD is of formula (III):



wherein R^{LL} is a linker for connection to the antibody.

18. The composition according to claim 16 or 17, wherein the anti-CD19 antibody comprises the CDRs of SEQ ID Nos: 2 and 8.

19. Use of the composition according to any one of claims 16-18 in the preparation of a medicament for treating a disorder in an individual, wherein the treatment is as defined in any one of claims 1-12.